Article Information
History
- December 27, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Daniel Andrews1,2,†,
- Douglas L. Arnold2,3,4,
- Danilo Bzdok1,2,5,
- Simon Ducharme2,6,7,
- Howard Chertkow8,9,10,11,
- D. Louis Collins1,2,3,
- the Alzheimer’s Disease Neuroimaging Initiative*
- 1Department of Biomedical Engineering, McGill University, Montreal, Canada
- 2McConnell Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada
- 3Department of Neurology and Neurosurgery, McGill University, Montreal, Canada
- 4NeuroRx Research, Montreal, Canada
- 5Mila – Quebec Artificial Intelligence Institute, Montreal, Canada
- 6Department of Psychiatry, McGill University, Montreal, Canada
- 7Douglas Mental Health University Institute, McGill University, Montreal, Canada
- 8Baycrest Centre for Geriatric Care, Toronto, Canada
- 9Kimel Centre for Brain Health and Wellness and Anne & Allan Bank Centre for Clinical Research Trials, Baycrest, Toronto, Canada
- 10Canadian Consortium on Neurodegeneration in Aging, Canada
- 11Division of Neurology, Department of Medicine, University of Toronto, Toronto, Canada
- ↵†Corresponding author:
Daniel Andrews, McConnell Brain Imaging Centre, Montreal Neurological Institute and Hospital, 3801 Rue University, H3A 2B4, Montreal, Quebec, Canada. Email: daniel.andrews2{at}mail.mcgill.ca
↵* Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (https://adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
Posted December 27, 2022.
Simulation-based power analysis could improve the design of clinical trials in Alzheimer’s disease
